CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of cholangiocarcinoma.
  
  LEARNING OBJECTIVES

  • Recognize the molecular heterogeneity of cholangiocarcinomas, and appreciate the biologic rationale for efforts to therapeutically exploit documented abnormalities in patients.
  • Review the recent FDA approval of pemigatinib for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 (fibroblast growth factor receptor 2) fusion or other rearrangement, and consider how this agent can be appropriately and safely integrated into clinical management algorithms.
  • Develop an understanding of available clinical trial findings with ivosidenib for patients with advanced cholangiocarcinoma and an IDH1 (isocitrate dehydrogenase 1) mutation to determine the applicability of this therapeutic strategy in current or future practice.
  • Recall available and emerging data with other agents and strategies currently in clinical testing for cholangiocarcinoma, and appropriately refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Mitesh J Borad, MD
  Associate Professor of Medicine
  Mayo Clinic College of Medicine and Science
  Co-Director, Precision Cancer Therapeutics Program
  Center for Individualized Medicine
  Program Leader, Gene and Virus Therapy Program
  Mayo Clinic Comprehensive Cancer Center
  Scottsdale, Arizona
  
  Consulting Agreements: Genentech, a member of the Roche Group, HUYA Bioscience International, The Lynx Group, Merck, Western Oncolytics, Sirnaomics, Zymeworks; Contracted Research: Adaptimmune, Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Celgene Corporation, EMD Serono Inc, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Puma Biotechnology Inc, QED Therapeutics, RedHill Biopharma Ltd, Relay Therapeutics, Senhwa Biosciences Inc, Sumitomo Dainippon Pharma Oncology Inc, Turnstone Biologics, Vyriad; Ownership Interest: ADC Therapeutics SA, Aveo Pharmaceuticals, Spectrum Pharmaceuticals.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Incyte Corporation and Taiho Oncology Inc.
  
  Release date: April 2021
  Expiration date: April 2022